WallStSmart

Phibro Animal Health Corporation (PAHC)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 877% more annual revenue ($14.30B vs $1.46B). PAHC leads profitability with a 6.3% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. PAHC earns a higher WallStSmart Score of 67/100 (B-).

PAHC

Strong Buy

67

out of 100

Grade: B-

Growth: 8.7Profit: 7.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 2.09

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PAHCUndervalued (+52.5%)

Margin of Safety

+52.5%

Fair Value

$108.58

Current Price

$57.01

$51.57 discount

UndervaluedFair: $108.58Overvalued

Intrinsic value data unavailable for VTRS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PAHC3 strengths · Avg: 9.3/10
Return on EquityProfitability
31.8%10/10

Every $100 of equity generates 32 in profit

EPS GrowthGrowth
752.0%10/10

Earnings expanding 752.0% YoY

Revenue GrowthGrowth
20.9%8/10

Revenue surging 20.9% year-over-year

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

PAHC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

Debt/EquityHealth
1.823/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PAHC

The strongest argument for PAHC centers on Return on Equity, EPS Growth, Revenue Growth. Revenue growth of 20.9% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : PAHC

The primary concerns for PAHC are PEG Ratio, Profit Margin, Debt/Equity. Debt-to-equity of 1.82 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

PAHC profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.80 — expect wider price swings.

PAHC is growing revenue faster at 20.9% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

PAHC scores higher overall (67/100 vs 50/100) and 20.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Phibro Animal Health Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?